BENIGN PROSTATIC HYPERPLASIA Nutritional and botanical therapeutic options

Benign prostatic hyperplasia (BPH, benign prostatic hypertrophy), a non-malignant abnormal growth of the prostate gland, affects almost all men in some degree as they age and can cause a significant disruption of lifestyle due to urinary outflow obstructive and irritative symptoms. An accumulation of estrogen in the aging prostate, along with increased conversion of testosterone to its more active metabolite dihydrotestosterone (DHT) seems to induce this aberrant hyperplasia. Fatty acid deficiencies, zinc deficiency, and amino acid deficiencies may also contribute to the disease process. Numerous studies confirm the mechanisms and efficacy of Serenoa repens, Pygeum africanum, and Urtica dioca in reducing DHT conversion and/or binding to nuclear receptors, and reducing or relieving BPH symptoms. Usage of the amino acids alanine, glycine, and glutamic acid, alone and in combination with the above botanicals, has been proven to be effective at reducing symptomatology and prostate size. Pollen preparations, antifungals, zinc, and essential fatty acid supplementation may also be helpful. (Alt Med Rev 1996;1:18-25)

[1]  T. Senge,et al.  Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia , 1995, The Lancet.

[2]  Bph Guideline Panel.  Benign Prostatic Hyperplasia: Diagnosis and Treatment , 1994 .

[3]  A. Witeska,et al.  Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. , 1993, Clinical therapeutics.

[4]  R. Nass,et al.  Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. , 1993, The Journal of clinical endocrinology and metabolism.

[5]  D. Russell,et al.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. , 1993, The Journal of clinical investigation.

[6]  M. Koronkowski,et al.  Finasteride: the first 5 alpha-reductase inhibitor. , 1993, Pharmacotherapy.

[7]  E. Crawford,et al.  Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatc hyperplasia , 1993 .

[8]  P. Belaiche,et al.  Clinical studies on the palliative treatment of prostatic adenoma with extract of Urtica root , 1991 .

[9]  J. S. Tenover.  Prostates, Pates, and Pimples: The Potential Medical Uses of Steroid 5α-Reductase Inhibitors , 1991 .

[10]  D. Russell,et al.  Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Aubert,et al.  [Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study]. , 1990, Wiener klinische Wochenschrift.

[12]  A. C. Buck,et al.  Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. , 1990, British journal of urology.

[13]  T. Harada,et al.  [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost]. , 1990, Hinyokika kiyo. Acta urologica Japonica.

[14]  C. Edwards,et al.  5 α-reductase activity in polycystic ovary syndrome , 1990, The Lancet.

[15]  D. Holt,et al.  Inhibitors of steroid 5 alpha-reductase in benign prostatic hyperplasia, male pattern baldness and acne. , 1989, Trends in pharmacological sciences.

[16]  .. PhD,et al.  Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate , 1989, Cancer.

[17]  Romero Gil,et al.  Use of amino acids as a combination in the treatment of prostatic hypertrophy , 1988 .

[18]  A. Saddique,et al.  The Effect of Permixon on Androgen Receptors , 1988, Acta obstetricia et gynecologica Scandinavica.

[19]  Jad James A. Duke,et al.  Handbook of Medicinal Herbs, Second Edition , 1987 .

[20]  J. OlléCarreras.  Our experience with a hexane extract of Serenoa repens in the treatment of benign prostatic hypertrophy , 1987 .

[21]  A. Bonnard,et al.  A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. , 1984, British journal of clinical pharmacology.

[22]  B. Dufour,et al.  [Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma]. , 1984, Annales d'urologie.

[23]  F. Habib,et al.  The effect of zinc on the 5α-reduction of testosterone by the hyperplastic human prostate gland , 1984 .

[24]  K. Schmidt.  [Effect of radix urticae extract and its several secondary extracts on blood SHBG in benign prostate hyperplasia]. , 1983, Fortschritte der Medizin.

[25]  F. Habib,et al.  Metal-androgen interrelationships in carcinoma and hyperplasia of the human prostate. , 1976, The Journal of endocrinology.

[26]  Schaffner Cp,et al.  Effect of candicidin and colestipol on the testes and prostate glands of BIO 87.20 hamsters. , 1976 .

[27]  J. Seebode,et al.  Candicidin: physiologic effect on prostate. , 1975, Urology.

[28]  G. Gormley,et al.  Finasteride: a clinical review. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  S. Dutkiewicz.  Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prazosin therapy. , 1995, Materia medica Polona. Polish journal of medicine and pharmacy.

[30]  J. Hankin,et al.  A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy , 1993, The Prostate.

[31]  P. Tauzin-Fin,et al.  [Prostate transurethral resection syndrome]. , 1992, Annales Francaise d'Anesthesie et de Reanimation.

[32]  L. Sanz,et al.  Le syndrome de résection transuréthrale de la prostate , 1992 .

[33]  J. S. Tenover.  Prostates, pates, and pimples. The potential medical uses of steroid 5 alpha-reductase inhibitors. , 1991, Endocrinology and metabolism clinics of North America (Print).

[34]  C. Edwards,et al.  5 alpha-reductase activity in polycystic ovary syndrome. , 1990, Lancet.

[35]  Y. Shiraiwa,et al.  Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. , 1990, Urologia internationalis.

[36]  M. Fratta,et al.  Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. , 1988, Clinical therapeutics.

[37]  J. Larue,et al.  [Zinc in the human prostate]. , 1985, Journal d'urologie.

[38]  Charles Jf,et al.  Zinc in the human prostate , 1985 .

[39]  M. Briley,et al.  Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. , 1984, Journal of steroid biochemistry.

[40]  M. Briley,et al.  Inhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblasts. , 1984, Journal of steroid biochemistry.

[41]  F. Habib,et al.  The effect of zinc on the 5 alpha-reduction of testosterone by the hyperplastic human prostate gland. , 1984, Journal of Steroid Biochemistry.

[42]  J. Stoff,et al.  Prostaglandins and the prostate: An hypothesis on the etiology of benign prostatic hyperplasia , 1983, The Prostate.

[43]  C. Schaffner,et al.  Effect of candicidin and colestipol on the testes and prostate glands of BIO 87.20 hamsters. , 1976, Investigative urology.